Novel antibodies against follicular non-Hodgkin's lymphoma

作者：van Meerten Tom; Hagenbeek Anton^*

来源：Best Practice & Research Clinical Haematology, 2011, 24(2): 231-256.

DOI：10.1016/j.beha.2011.03.002

• follicular Lymphoma
• monoclonal antibody
• CD20

The anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of patients with follicular B-cell lymphoma. With the combination of chemotherapy and rituximab the overall survival rate has increased with approximately 30%. Unfortunately, there is resistance to rituximab with relapse of the disease in about 60% of the patients during the first five years of treatment and eventually in all patients. To this end, there is a need to develop improved anti-CD20 monoclonal antibodies and antibodies that target other attractive molecules expressed on the follicular lymphoma cell. This review describes the development and clinical achievements so far of next generation anti-CD20 and other antibodies in the treatment of follicular B-cell lymphoma.

• 出版日期2011-6